# Geron Targets $240M RYTELO Revenue by 2026

> Geron expects $230-240 million in 2026 RYTELO revenue as community adoption grows
- Title: Geron Targets $240M RYTELO Revenue by 2026 · Yahoo Finance
- Summary: Geron expects $230-240 million in 2026 RYTELO revenue as community adoption grows Geron's RYTELO revenue guidance rises to $240 million by 2026 with strong…
- Keywords: geron, rytelo, myelodysplastic, community oncology, nfl, telomerase, imelstat, myelofibrosis, phase 3, cash reserves, operating expenses, fda
- Source: Yahoo Finance — https://finance.yahoo.com/healthcare/articles/geron-eyes-high-end-2026-130243606.html
- Published: 2026-09-16T13:02:43+00:00
- Read time: 1 min
- Topics: geron, rytelo, myelodysplastic, community oncology, nfl, telomerase, imelstat, myelofibrosis, phase 3, cash reserves, operating expenses, fda
## 2026 Revenue Update
Geron now expects $230-240 million in 2026 RYTELO revenue, toward the high end of its previous $220-240 million guidance.

> Geron expects 2026 RYTELO revenue of approximately $230 million to $240 million
## Record Quarterly Sales
The company reported $57.5 million in net revenue for the latest quarter, its highest since RYTELO's July 2024 launch.

> Geron reported $57.5 million in net revenue in its latest quarter
## Community Focus Shift
Geron is targeting community oncology practices for 80% of its lower-risk MDS market, adding 100-200 new accounts quarterly.

> Commercial efforts are shifting toward community oncology practices, which account for about 80% of the lower-risk MDS market
## Early-Line Growth
34% of Geron's business comes from first- and second-line patients, with expectations for growing early-line mix over time.

> 34% of Geron's business, measured using a 12-month lookback, came from first- and second-line patients
## European Strategy
Geron plans to outline its European commercialization strategy before year-end without pursuing traditional country-by-country builds.

> Geron plans to provide an ex-U.S. strategy, particularly for Europe, before year-end
## Myelofibrosis Trial
The 327-patient IMpactMF Phase 3 trial for relapsed myelofibrosis compares imetelstat with best available therapy.

> Geron also discussed its IMpactMF Phase 3 trial in relapsed or refractory myelofibrosis following treatment with a JAK inhibitor
## Cash Reserves
Geron has over $300 million in cash and reiterated 2026 operating expense guidance of $230-240 million.

> Geron had more than $300 million in cash and recently hired its first chief business officer
## FDA Approval Impact
RYTelo received FDA panel approval in July 2024 as the first telomerase inhibitor for lower-risk MDS patients.

> RYTelo, or imetelstat, was launched in July 2024 as the first telomerase inhibitor for patients with lower-risk myelodysplastic syndromes
## Key takeaway

Geron's RYTELO revenue guidance rises to $240 million by 2026 with strong community oncology adoption